Effect of the Nutraceutical Micodigest 2.0 on the Complication Rate of Colorectal Cancer Surgery With Curative Intent: Protocol for a Placebo-Controlled Double-blind Randomized Clinical Trial

Cristina Regueiro, Laura Codesido, Laura García-Nimo, Sara Zarraquiños, David Remedios, Arturo Rodríguez-Blanco, Esteban Sinde, Catalina Fernández-de-Ana, Joaquín Cubiella, Cristina Regueiro, Laura Codesido, Laura García-Nimo, Sara Zarraquiños, David Remedios, Arturo Rodríguez-Blanco, Esteban Sinde, Catalina Fernández-de-Ana, Joaquín Cubiella

Abstract

Background: Most colorectal cancer patients diagnosed are candidates for surgical resection with curative intent, although colorectal surgery is associated with some complications that could be life-threatening. Antibiotic prophylaxis is commonly used for the prevention of infectious postoperative complications. However, this intervention can change the composition of intestinal microbiota and promote adverse inflammatory outcomes in colorectal cancer patients. The combination of different fungal extracts could be beneficial because of their role in gut microbiota modulation and their anti-inflammatory activity.

Objective: Based on this hypothesis, we have designed a double-bind, randomized clinical trial to evaluate the effect of the nutraceutical fungal extract Micodigest 2.0 on complications of surgery for colorectal cancer resection.

Methods: Colorectal cancer candidates for surgery will be considered for inclusion in the study. After evaluation by the multidisciplinary tumor board, patients who meet selection criteria will be screened, stratified according to tumor location, and randomly allocated to be treated with Micodigest 2.0 or placebo. Treatment will be continued until admission for surgery (4-6 weeks). Participants will undergo a medical and clinical evaluation including baseline and preadmission quality of life, microbiome composition, inflammatory and nutritional status, adverse events, and adherence assessments. The main end point of the study is the surgery complication rate. We will evaluate complications using the Clavien-Dindo classification. It will be necessary to recruit 144 patients to find a relevant clinical difference. We will also evaluate the effect of the nutraceutical on microbiome composition, inflammatory response, nutritional status, and quality of life, as well as the effect of these variables on surgical complications.

Results: This study was funded in 2020 by the Center for Industrial Technology Development. Recruitment began in September 2021 and is expected to be completed in September 2022. Data will be analyzed and the results will be disseminated in 2023.

Conclusions: The results of this protocol study could help to reduce surgery complications in patients with colorectal cancer using the new treatment Micodigest. This study could also identify new features associated with colorectal surgery complications. In summary, this study trial could improve the management of colorectal cancer patients.

Trial registration: Clinical Trials.gov NCT04821258; https://ichgcp.net/clinical-trials-registry/NCT04821258.

International registered report identifier (irrid): DERR1-10.2196/34292.

Keywords: cancer; colon; colorectal; colorectal cancer; gut microbiota; inflammatory pattern; nutraceutical; nutritional status; postsurgery; surgery complications.

Conflict of interest statement

Conflicts of Interest: CFA belongs to the research and development team of Hifas da Terra.

©Cristina Regueiro, Laura Codesido, Laura García-Nimo, Sara Zarraquiños, David Remedios, Arturo Rodríguez-Blanco, Esteban Sinde, Catalina Fernández-de-Ana, Joaquín Cubiella. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 16.05.2022.

References

    1. Cancer Today. International Agency for Research on Cancer. [2020-04-23]. .
    1. Gutierrez-Stampa MA, Aguilar V, Sarasqueta C, Cubiella J, Portillo I, Bujanda L. Impact of the faecal immunochemical test on colorectal cancer survival. BMC Cancer. 2020 Jul 01;20(1):616. doi: 10.1186/s12885-020-07074-y. 10.1186/s12885-020-07074-y
    1. Quintana JM, Antón-Ladisla A, González N, Lázaro S, Baré M, Fernández de Larrea N, Redondo M, Briones E, Escobar A, Sarasqueta C, García-Gutierrez S, REDISSEC-CARESS/CCR group Outcomes of open versus laparoscopic surgery in patients with colon cancer. Eur J Surg Oncol. 2018 Sep;44(9):1344–1353. doi: 10.1016/j.ejso.2018.05.030.S0748-7983(18)31110-7
    1. Larach SW, Patankar SK, Ferrara A, Williamson PR, Perozo SE, Lord AS. Complications of laparoscopic colorectal surgery. Analysis and comparison of early vs. latter experience. Dis Colon Rectum. 1997 May;40(5):592–596. doi: 10.1007/BF02055385.
    1. Alves A, Panis Y, Mathieu P, Mantion G, Kwiatkowski F, Slim K, Association Française de Chirurgie Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg. 2005 Mar;140(3):278–283. doi: 10.1001/archsurg.140.3.278.140/3/278
    1. Tevis SE, Kennedy GD. Postoperative complications: looking forward to a safer future. Clin Colon Rectal Surg. 2016 Sep;29(3):246–252. doi: 10.1055/s-0036-1584501. 00753
    1. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187–196. doi: 10.1097/SLA.0b013e3181b13ca2.
    1. Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev. 2014 May 09;(5):CD001181. doi: 10.1002/14651858.CD001181.pub4.
    1. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA, American Society of Health-System Pharmacists. Infectious Disease Society of America. Surgical Infection Society. Society for Healthcare Epidemiology of America Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013 Feb 01;70(3):195–283. doi: 10.2146/ajhp120568.70/3/195
    1. Rollins KE, Javanmard-Emamghissi H, Acheson AG, Lobo DN. The role of oral antibiotic preparation in elective colorectal surgery: a meta-analysis. Ann Surg. 2019 Jul;270(1):43–58. doi: 10.1097/SLA.0000000000003145.
    1. Scarborough JE, Mantyh CR, Sun Z, Migaly J. Combined mechanical and oral antibiotic bowel preparation reduces incisional surgical site infection and anastomotic leak rates after elective colorectal resection: an analysis of colectomy-targeted ACS NSQIP. Ann Surg. 2015 Aug;262(2):331–337. doi: 10.1097/SLA.0000000000001041.
    1. Abis GSA, Stockmann HBAC, Bonjer HJ, van Veenendaal N, van Doorn-Schepens MLM, Budding AE, Wilschut JA, van Egmond M, Oosterling SJ, SELECT trial study group Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial) Br J Surg. 2019 Mar;106(4):355–363. doi: 10.1002/bjs.11117.
    1. Espin Basany E, Solís-Peña A, Pellino G, Kreisler E, Fraccalvieri D, Muinelo-Lorenzo M, Maseda-Díaz O, García-González JM, Santamaría-Olabarrieta M, Codina-Cazador A, Biondo S. Preoperative oral antibiotics and surgical-site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):729–738. doi: 10.1016/S2468-1253(20)30075-3.S2468-1253(20)30075-3
    1. Adiamah A, Skořepa P, Weimann A, Lobo DN. The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis. Ann Surg. 2019 Aug;270(2):247–256. doi: 10.1097/SLA.0000000000003256.
    1. Chowdhury AH, Adiamah A, Kushairi A, Varadhan KK, Krznaric Z, Kulkarni AD, Neal KR, Lobo DN. Perioperative probiotics or synbiotics in adults undergoing elective abdominal surgery: a systematic review and meta-analysis of randomized controlled trials. Ann Surg. 2020 Jun;271(6):1036–1047. doi: 10.1097/SLA.0000000000003581.00000658-202006000-00012
    1. Alam A, Neish A. Role of gut microbiota in intestinal wound healing and barrier function. Tissue Barriers. 2018;6(3):1539595. doi: 10.1080/21688370.2018.1539595.
    1. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012 Sep 13;489(7415):242–249. doi: 10.1038/nature11552.nature11552
    1. Stavrou G, Kotzampassi K. Gut microbiome, surgical complications and probiotics. Ann Gastroenterol. 2017;30(1):45–53. doi: 10.20524/aog.2016.0086. AnnGastroenterol-30-45
    1. Ferrer M, Martins dos Santos VAP, Ott SJ, Moya A. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut Microbes. 2014;5(1):64–70. doi: 10.4161/gmic.27128. 27128
    1. Shimizu K, Ogura H, Goto M, Asahara T, Nomoto K, Morotomi M, Yoshiya K, Matsushima A, Sumi Y, Kuwagata Y, Tanaka H, Shimazu T, Sugimoto H. Altered gut flora and environment in patients with severe SIRS. J Trauma. 2006 Jan;60(1):126–133. doi: 10.1097/01.ta.0000197374.99755.fe.00005373-200601000-00018
    1. Lapthorne S, Bines JE, Fouhy F, Dellios NL, Wilson G, Thomas SL, Scurr M, Stanton C, Cotter PD, Pereira-Fantini PM. Changes in the colon microbiota and intestinal cytokine gene expression following minimal intestinal surgery. World J Gastroenterol. 2015 Apr 14;21(14):4150–4158. doi: 10.3748/wjg.v21.i14.4150.
    1. Kong C, Gao R, Yan X, Huang L, He J, Li H, You J, Qin H. Alterations in intestinal microbiota of colorectal cancer patients receiving radical surgery combined with adjuvant CapeOx therapy. Sci China Life Sci. 2019 Sep;62(9):1178–1193. doi: 10.1007/s11427-018-9456-x.10.1007/s11427-018-9456-x
    1. Ottosson F, Brunkwall L, Ericson U, Nilsson PM, Almgren P, Fernandez C, Melander O, Orho-Melander M. Connection between BMI-related plasma metabolite profile and gut microbiota. J Clin Endocrinol Metab. 2018 Apr 01;103(4):1491–1501. doi: 10.1210/jc.2017-02114.4834036
    1. Yin C, Noratto GD, Fan X, Chen Z, Yao F, Shi D, Gao H. The impact of mushroom polysaccharides on gut microbiota and its beneficial effects to host: a review. Carbohydr Polym. 2020 Dec 15;250:116942. doi: 10.1016/j.carbpol.2020.116942.S0144-8617(20)31115-2
    1. Ma G, Kimatu BM, Zhao L, Yang W, Pei F, Hu Q. In vivo fermentation of a Pleurotus eryngii polysaccharide and its effects on fecal microbiota composition and immune response. Food Funct. 2017 May 24;8(5):1810–1821. doi: 10.1039/c7fo00341b.
    1. Chang C, Lin C, Lu C, Martel J, Ko Y, Ojcius DM, Tseng S, Wu T, Chen YM, Young JD, Lai H. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. 2015 Jun 23;6:7489. doi: 10.1038/ncomms8489. doi: 10.1038/ncomms8489.ncomms8489
    1. Diling C, Chaoqun Z, Jian Y, Jian L, Jiyan S, Yizhen X, Guoxiao L. Immunomodulatory activities of a fungal protein extracted from through regulating the gut microbiota. Front Immunol. 2017;8:666. doi: 10.3389/fimmu.2017.00666. doi: 10.3389/fimmu.2017.00666.
    1. Nowak R, Nowacka-Jechalke N, Juda M, Malm A. The preliminary study of prebiotic potential of Polish wild mushroom polysaccharides: the stimulation effect on Lactobacillus strains growth. Eur J Nutr. 2018 Jun;57(4):1511–1521. doi: 10.1007/s00394-017-1436-9. 10.1007/s00394-017-1436-9
    1. Hess J, Wang Q, Gould T, Slavin J. Impact of agaricus bisporus mushroom consumption on gut health markers in healthy adults. Nutrients. 2018 Oct 02;10(10):1402. doi: 10.3390/nu10101402. nu10101402
    1. Barbieri A, Quagliariello V, Del Vecchio V, Falco M, Luciano A, Amruthraj NJ, Nasti G, Ottaiano A, Berretta M, Iaffaioli RV, Arra C. Anticancer and anti-inflammatory properties of ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment. Nutrients. 2017 Feb 28;9(3):210. doi: 10.3390/nu9030210. nu9030210
    1. Chen X, Hu Z, Yang X, Huang M, Gao Y, Tang W, Chan SY, Dai X, Ye J, Ho PC, Duan W, Yang H, Zhu Y, Zhou S. Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. Int Immunopharmacol. 2006 Mar;6(3):499–508. doi: 10.1016/j.intimp.2005.08.026.S1567-5769(05)00253-5
    1. Nie Y, Lin Q, Luo F. Effects of non-starch polysaccharides on inflammatory bowel disease. Int J Mol Sci. 2017 Jun 27;18(7):1372. doi: 10.3390/ijms18071372. ijms18071372
    1. Jiang J, Wojnowski R, Jedinak A, Sliva D. Suppression of proliferation and invasive behavior of human metastatic breast cancer cells by dietary supplement BreastDefend. Integr Cancer Ther. 2011 Jun;10(2):192–200. doi: 10.1177/1534735410386953. 1534735410386953
    1. Jakopovich I. New dietary supplements from medicinal mushrooms: Dr Myko San—a registration report. Int J Med Mushrooms. 2011;13(3):307–313. doi: 10.1615/intjmedmushr.v13.i3.110.
    1. Zaidman B, Yassin M, Mahajna J, Wasser SP. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol. 2005 Jun;67(4):453–468. doi: 10.1007/s00253-004-1787-z.
    1. Borchers AT, Krishnamurthy A, Keen CL, Meyers FJ, Gershwin ME. The immunobiology of mushrooms. Exp Biol Med (Maywood) 2008 Mar;233(3):259–276. doi: 10.3181/0708-MR-227.233/3/259
    1. Wasser SP. Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl Microbiol Biotechnol. 2011 Mar;89(5):1323–1332. doi: 10.1007/s00253-010-3067-4.
    1. Chan A, Tetzlaff JM, Gøtzsche P, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 08;346:e7586. doi: 10.1136/bmj.e7586.
    1. Ræder H, Henriksen C, Bøhn SK, O de Fey Vilbo A, Henriksen HB, Kværner AS, Rolid K, Paur I, Smeland S, Blomhoff R. Agreement between PG-SGA category and fat-free mass in colorectal cancer patients. Clin Nutr ESPEN. 2018 Oct;27:24–31. doi: 10.1016/j.clnesp.2018.07.005.S2405-4577(18)30003-2
    1. Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, Santed R, Valderas JM, Ribera A, Domingo-Salvany A, Alonso J. [The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments] Gac Sanit. 2005;19(2):135–150. doi: 10.1157/13074369. 13074370
    1. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 5th Edition. [2020-11-17]. .

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다